Arena Pharmaceuticals Inc (ARNA) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ARNA Annual Balance Sheets →
A period-by-period view of the balance sheet from Arena Pharmaceuticals Inc to Dec 31 2020 helps clarify how Dec 31 2021's financial structure has changed over time.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2021)
(Sep 30 2021) (Jun 30 2021) (Mar 31 2021) (Dec 31 2020)
Assets
Cash & cash equivalent224.57
Available-for-sale Securities, Debt Securities, Current MA325.90
Cash & Short-term Investments549.00
Prepaid Expense And Other Assets Current19.00
Total Current Assets569.47
Equipment/Property/Plant Net19.13
Long-term investments160.80
Other Assets, Noncurrent35.32
Total Assets784.71
Liabilities
Accounts Payable and Other Accrued Liabilities, Current32.14
Total Current Liabilities66.32
Total Long-term Debt0.00
Other liabilities, Noncurrent8.99
Sale Leaseback Financing Obligations Current5.05
Accrued Clinical And Preclinical Study Fees29.13
Sale Leaseback Financing Obligations Noncurrent36.16
Total Liabilities111.47
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock2,797.68
Retained Earnings / Accumulated Deficit-2,124.16
Other Equity-0.28
Common Stockholder's Equity673.24
Total Stockholder's Equity673.24
Liabilities & Stockholder's Equity784.71
4 historic quarters locked

Sign in to unlock the full Arena Pharmaceuticals Inc balance sheet history.

About Arena Pharmaceuticals Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001080709-22-000008

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.